How much does a box of Enfortumab cost in 2024?

Enfortumab vedotin is a targeted therapy drug used to treat advanced or metastatic urothelial cancer (urothelial cancer). It is an immune cell-infiltrating cancer commonly found in urinary system tissues such as the bladder, renal pelvis, and ureters. This type of cancer typically has a poor prognosis and has limited response to traditional chemotherapy and targeted therapies.

Ennosumab is not currently available in China, so patients cannot purchase it domestically and need to purchase ennosumab through overseas channels. There are only enromonumab original drugs abroad, mainly Japanese original drugs, which cost more than 10,000 yuan and are relatively expensive.

Ennosumab is a chimeric protein drug composed of a monoclonal antibody combined with a cytotoxin. It works by targeting cancer cells that express Nectin-4, a protein that is overexpressed in a variety of cancers. Once ennosumab binds to Nectin-4 on the surface of cancer cells, it releases cytotoxins, leading to cancer cell death.

Ennosumab is a targeted therapy that is more specific than traditional chemotherapy and can cause less damage to healthy cells while providing more effective cancer treatments. Clinical trials have shown that ennozumab exhibits significant efficacy in the treatment of patients with advanced urothelial cancer, including those whose disease has progressed despite prior chemotherapy.

However, like other drugs, ennozumab may cause some side effects, including fatigue, nausea, vomiting, rash, diarrhea, and infection. Therefore, when treated with ennozumab, doctors will typically monitor the patient's response and take necessary steps to manage any side effects that occur.

Overall, ennosumab represents an important advance in the treatment of advanced urothelial cancer, providing a new treatment option for patients who have previously had limited treatment options. However, patients should consult their doctor before undergoing treatment to learn about its benefits and possible risks.